Latest Kidney Disease News

Page 6 of 8
Archer Materials has made notable advances in its quantum computing and biosensor technologies during FY25, alongside leadership changes and a widened net loss. The company’s progress signals growing momentum in its commercialisation efforts.
Sophie Babbage
Sophie Babbage
28 Aug 2025
Dimerix Limited reported a 22% reduction in its FY2025 loss to $13.25 million, driven by strong licensing revenues and advancing its pivotal Phase 3 clinical trial for DMX-200. The company secured new global partnerships valued at up to AU$1.4 billion, bolstering its cash reserves and commercial prospects.
Ada Torres
Ada Torres
28 Aug 2025
PYC Therapeutics has escalated dosing to the highest level in its Phase 1a trial of PYC-003 and begun dosing patients with Polycystic Kidney Disease, marking key progress toward regulatory milestones.
Ada Torres
Ada Torres
8 Aug 2025
Proteomics International Laboratories has secured $12 million to fast-track its precision diagnostic tests, including the US launch of PromarkerD for diabetic kidney disease, backed by a new AMA billing code. The company also advances its pipeline with new patents and commercial partnerships.
Ada Torres
Ada Torres
28 July 2025
Dimerix has secured a significant licensing agreement with Amicus Therapeutics for its kidney disease drug candidate DMX-200 in the US, receiving a US$30 million upfront payment and advancing its Phase 3 trial with FDA endorsement of a key clinical endpoint.
Ada Torres
Ada Torres
25 July 2025
PYC Therapeutics reports solid progress across its four RNA therapeutic programs targeting genetic diseases, backed by a strong cash position extending runway beyond 2027.
Ada Torres
Ada Torres
21 July 2025
Archer Materials advances its quantum computing and medical diagnostics technologies, extending key partnerships and forming a new advisory board while maintaining a strong cash position to fuel development.
Sophie Babbage
Sophie Babbage
14 July 2025
PYC Therapeutics has secured Safety Review Committee approval to escalate dosing in its PYC-003 clinical trial and will soon begin dosing patients with Polycystic Kidney Disease, marking a pivotal step forward.
Ada Torres
Ada Torres
7 July 2025
Proteomics International has secured a dedicated US reimbursement code for its next-generation PromarkerD test, a key step towards broader adoption in diabetic kidney disease diagnostics.
Ada Torres
Ada Torres
3 July 2025
Dimerix Limited has received a significant milestone payment from its Japanese partner FUSO Pharmaceutical, marking progress in the Phase 3 clinical trial of DMX-200 for kidney disease. This payment underscores the growing momentum behind Dimerix’s global licensing strategy.
Ada Torres
Ada Torres
30 June 2025
Proteomics International has launched PromarkerD, a pioneering blood test that predicts diabetic kidney disease years before symptoms, marking its entry into the vast US healthcare market.
Ada Torres
Ada Torres
20 June 2025
Dimerix has reached a key milestone by dosing 200 adult patients in its Phase 3 ACTION3 trial for FSGS, progressing steadily toward full recruitment expected in late 2025.
Ada Torres
Ada Torres
13 June 2025

Browse the archive

Full archive